Close
Close

AstraZeneca - PSR Ovarian Cancer With a BRCA Mutation

Partner

Not provided

Rare Disease

PSR Ovarian Cancer With a BRCA Mutation

Sponsor

AstraZeneca

Access Program Information

This is a single-arm, open label, expanded access program to provide access to olaparib tablets for relapsed high-grade epithelial ovarian cancer patients (including patients with primary peritoneal and / or fallopian tube cancer) with BRCA mutations (documented mutation in BRCA1 or BRCA2 that is predicted to be deleterious or suspected deleterious [known or predicted to be detrimental/lead to loss of function]) who have responded following platinum based chemotherapy. Patients may continue to receive study treatment until disease progression as assessed by the investigator according to local standard clinical practice or any other discontinuation criteria are met.

Contact
Locations
  • Japan

Free Newsletter